Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Benitec Biopharma Limited (BNTC : NSDQ)

• Company Description    Benitec Biopharma Limited is a biotechnology company which developed a patented gene silencing technology delivered by gene therapy called DNA directed RNA interference. The company is developing ddRNAi-based therapeutics for chronic and life-threatening human conditions including hepatitis C and B, drug resistant lung cancer and wet age-related macular degeneration. Benitec Biopharma Limited is based in Sydney, Australia. Number of Employees: 14

• Price / Volume Information    Yesterday's Closing Price: $1.08 Daily Weekly Monthly 20 Day Moving Average: 24,804 shares Shares Outstanding: 8.17 (millions) Market Capitalization: $8.83 (millions) Beta: 1.58 52 Week High: $5.07 52 Week Low: $1.04 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -46.80% -41.71% 12 Week -57.65% -54.04% Year To Date -58.78% -50.98%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 3940 Trust Way - Hayward,CA 94545 USA ph: 510-780-0819 fax: 61 (0)3 9966-9923 jmorakis@mgroupsc.com http://www.benitec.com

• General Corporate Information    Officers Jerel Banks - Chief Executive Officer; Director Megan Boston - Director J. Kevin Buchi - Director Peter Francis - Director Edward Smith - Director Peer Information Benitec Biopharma Limited (CORR.) Benitec Biopharma Limited (RSPI) Benitec Biopharma Limited (CGXP) Benitec Biopharma Limited (BGEN) Benitec Biopharma Limited (GTBP) Benitec Biopharma Limited (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 08205P100 SIC: 2834 Fiscal Year Fiscal Year End: June Last Reported Quarter: 03/01/22 Next Expected EPS Date: 09/19/22 Share - Related Items Shares Outstanding: 8.17 Most Recent Split Date: 4.00 (0.67:1) Beta: 1.58 Market Capitalization: $8.83 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.43 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.08 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 1.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 09/19/22

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 0.81 Price/Cash Flow: - Price / Sales: 149.58 EPS Growth vs. Year Ago Period: 99.76% vs. Previous Quarter: 99.66% Sales Growth vs. Year Ago Period: 4,700.00% vs. Previous Quarter: 92.00% ROE 03/31/22 - -111.03 12/31/21 - -124.21 09/30/21 - -106.22 ROA 03/31/22 - -96.62 12/31/21 - -106.68 09/30/21 - -95.13 Current Ratio 03/31/22 - - 12/31/21 - 5.11 09/30/21 - 10.23 Quick Ratio 03/31/22 - - 12/31/21 - 5.11 09/30/21 - 10.23 Operating Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Net Margin 03/31/22 - - 12/31/21 - - 09/30/21 - - Pre-Tax Margin 03/31/22 - - 12/31/21 - -63,492.85 09/30/21 - -405,224.97 Book Value 03/31/22 - - 12/31/21 - 1.33 09/30/21 - 1.89 Inventory Turnover 03/31/22 - - 12/31/21 - - 09/30/21 - - Debt-to-Equity 03/31/22 - - 12/31/21 - 0.06 09/30/21 - 0.05 Debt-to-Capital 03/31/22 - - 12/31/21 - 6.05 09/30/21 - 4.68

Powered by Zacks Investment Research ©